Trial Profile
A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Jun 2009 Actual patient number changed from 254 to 255 as reported by ClinicalTrials.gov.
- 12 May 2009 Actual patient number changed from 255 to 254 as reported by ClinicalTrials.gov.
- 05 May 2009 Additional locations Brazil, Germany, Greece, Spain, Turkey and actual patient number (255) identified as reported by ClinicalTrials.gov.